- SenesTech, a rodent fertility control expert, just announced the launch of its Evolve(TM) Soft Bait, representing an innovative, patent pending, minimum risk alternative treatment to reduce fertility in rats
- This product adds to the company’s growing line of pest control solutions, such as ContraPest(R), a highly palatable liquid contraceptive bait
- SenesTech’s management has lauded this milestone, noting how the product, with its non-liquid form, will dramatically increase its addressable market
- The company plans to market it to professionals as well as directly to consumers through e-commerce and big-box stores
SenesTech (NASDAQ: SNES), a rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats, just announced the launch of its Evolve(TM) Soft Bait (“Evolve”), a minimum-risk solution in a new form, designed to reduce fertility in rats. As a potential solution to the root cause of pest problems – rats’ ability to rapidly reproduce – Evolve offers an effective product in a format that is familiar to pest control professionals and at a price that is comparable to traditional rodenticides. Results can be seen in as little as four to six weeks (https://ibn.fm/yS388).
Evolve(TM) adds to SenesTech’s growing line of pest control solutions, such as ContraPest(R), a highly palatable liquid rat contraceptive bait. Like the company’s other products, Evolve(TM) promises to offer a long-term solution to pest problems, effective fertility control, and a user-friendly format perfect for professionals and consumers. The product also seamlessly integrates with pest management programs while addressing infestation at its source, all made possible by its high palatability.
“Evolve(TM) was developed to offer customers a soft bait product that has similar efficacy to ContraPest(R), but in a format that is easier to deploy and predominantly used in the rodenticide market,” noted Joel Fruendt, President and CEO of SenesTech.
SenesTech’s management has lauded this milestone, noting how the product will geometrically increase its addressable market, all while also creating value for its shareholders.
“The addition of Evolve(TM) to our portfolio of fertility control products will increase our obtainable market at a price point that is very attractive to the end user,” noted Fruendt.
The company plans to target professionals and consumers through e-commerce and big-box stores. Its management is confident that this approach will bring its products closer to residential users while expanding the company’s reach to a broader array of consumers.
For more information, visit the company’s website at www.SenesTech.com.
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN